Is there material hazard to treatment with intravenous iron?

被引：8

作者：

Fishbane, S ^{[1
]}

Maesaka, JK ^{[1
]}

Mittal, SK ^{[1
]}

机构：

[1] Winthrop Univ Hosp, Mineola, NY USA

来源：

关键词：

D O I：

10.1093/ndt/14.11.2595

中图分类号：

R3 [基础医学]; R4 [临床医学];

学科分类号：

1001 ; 1002 ; 100602 ;

摘要：

引用

页码：2595 / 2598

页数：4

共 41 条

[11] ESCHBACH JW, 1983, CONTRIB NEPHROL, V38, P129
[12] EVANS RW, 1990, JAMA-J AM MED ASSOC, V263, P825
[13] REDUCTION IN RECOMBINANT-HUMAN-ERYTHROPOIETIN DOSES BY THE USE OF CHRONIC INTRAVENOUS IRON SUPPLEMENTATION
FISHBANE, S
FREI, GL
MAESAKA, J
[J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1995, 26 (01) : 41 - 46
[14] The safety of intravenous iron dextran in hemodialysis patients
Fishbane, S
Ungureanu, VD
Maesaka, JK
Kaupke, CJ
Lim, V
Wish, J
[J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1996, 28 (04) : 529 - 534
[15] GEISSER P, 1992, ARZNEIMITTEL-FORSCH, V42-2, P1439
[16] GRANOLLERAS C, 1993, ERYTHROPOIETIN, P211
[17] INTRAVENOUS IRON DEXTRAN IN CLINICAL MEDICINE
HAMSTRA, RD
BLOCK, MH
SCHOCKET, AL
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1980, 243 (17): : 1726 - 1731
[18] Hoen B, 1998, J AM SOC NEPHROL, V9, P869
[19] HOEN B, 1995, NEPHROL DIAL TRANSPL, V10, P377
[20] Kowalski EA, 1997, J AM SOC NEPHROL, V8, pA1115